# Real-world Study of Aflibercept 8 mg in nAMD

> **NCT07640997** · — · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** Aflibercept 8mg

## Key facts

- **NCT ID:** NCT07640997
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640997, "Real-world Study of Aflibercept 8 mg in nAMD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*